Leeds's St James's University Hospital haematology — one of Yorkshire's leading haematology programmes — manages ITP patients from across West Yorkshire requiring dose-escalated Eltrombopag. Platify 50 provides Leeds patients with affordable second-step dose Eltrombopag when NHS specialist commissioning delays or private prescription access creates need for supplementary supply at reduced cost.
Visit unnatipharmax.com | 📱 +91 82650 41513 | 📧 Unnatipharmax@gmail.com
FAQ 1: What is secondary ITP and how is it managed differently from primary ITP with Platify 50?Primary ITP is immune thrombocytopenia with no identified underlying cause — the autoimmune attack on platelets arises spontaneously. Secondary ITP occurs in the context of an underlying condition that drives or contributes to the immune-mediated platelet destruction. Common causes of secondary ITP include: autoimmune conditions (lupus/SLE, antiphospholipid syndrome, rheumatoid arthritis), infections (Hepatitis C, HIV — historically important, drug-induced immunosuppression), lymphoproliferative disorders (CLL, Hodgkin's lymphoma), and certain medications (heparin, quinine, vancomycin). Managing secondary ITP requires treating the underlying cause alongside platelet support — treating the Hepatitis C (with Resof L) may resolve HCV-associated ITP; treating CLL may improve lymphoma-associated ITP. Platify 50 provides platelet support while underlying cause treatment is pursued, but Leeds haematologists always investigate for and address secondary causes before establishing a primary ITP diagnosis and committing to long-term TPO-RA therapy. FAQ 2: Can Platify 50 be combined with corticosteroids or is it always used as a steroid-sparing replacement?Platify 50 (Eltrombopag) can be used both alongside corticosteroids and as a steroid-replacement strategy — the clinical context determines the approach. In newly diagnosed ITP with very low platelet counts (below 10-20 × 10⁹/L) and bleeding symptoms, short-course high-dose dexamethasone or prednisolone is given first for rapid platelet rise — TPO-RAs take 1-2 weeks to produce their full effect and aren't fast enough alone for emergency situations. Platify 50 may then be added if steroids alone achieve inadequate response, or overlapped as steroids are tapered to maintain platelet counts as steroid doses are reduced. In chronic refractory ITP where steroids have failed or caused unacceptable side effects, Platify 50 replaces rather than supplements steroids. Leeds haematologists discuss the steroid-sparing role of Platify 50 explicitly with patients — reducing steroid exposure significantly improves long-term quality of life by eliminating weight gain, bone thinning, glucose dysregulation, and mood effects of prolonged corticosteroid use. FAQ 3: What is the Fostamatinib option for Leeds ITP patients who fail Platify 50?Fostamatinib (Tavalisse) is a novel oral SYK (spleen tyrosine kinase) inhibitor approved for chronic ITP in adults who have had insufficient response to previous treatment — representing a different mechanism from TPO-RAs. While TPO-RAs like Platify 50 stimulate platelet production to overcome destruction, Fostamatinib blocks the Fc-receptor signalling pathway in macrophages that mediates platelet phagocytosis — reducing platelet destruction rather than increasing production. In the FIT trials, Fostamatinib produced stable platelet responses in approximately 18% of patients who had failed prior treatments including TPO-RAs. It is available in the UK through NICE approval for patients with chronic ITP who have had at least two prior therapies. Leeds haematologists consider Fostamatinib for ITP patients who fail to achieve adequate response with Platify 50 at maximum dose (75mg) or who develop unacceptable side effects, before proceeding to more invasive options like splenectomy or immunosuppressive salvage regimens. FAQ 4: How does ITP affect dental health and what should Leeds ITP patients tell their dentist?ITP patients should always inform their dentist about their platelet disorder and current platelet count before any dental procedure. The dentist needs to know: your current platelet count (check with Leeds haematology if uncertain), your current ITP medications including Platify 50 dose, any recent steroid use (affects infection risk and wound healing), and your haematologist's contact details. For routine dental hygiene (non-invasive scaling, check-ups), platelet counts above 20 × 10⁹/L are generally adequate with local haemostatic measures (pressure, tranexamic acid mouthwash). For extractions and invasive procedures, target platelet counts are typically 50-80 × 10⁹/L — achieved through Platify 50 dose optimisation before the appointment. Tranexamic acid (Cyclokapron) 5% mouthwash held in the mouth for 5-10 minutes before and after dental procedures significantly reduces post-procedural bleeding in ITP patients and is available on Leeds NHS prescription. Communication between the dental team and Leeds haematology ensures safe planning for all dental interventions. FAQ 5: What is the impact of COVID-19 vaccines on ITP — can Leeds patients on Platify 50 be safely vaccinated?COVID-19 vaccination has a documented association with immune thrombocytopenia — both new-onset ITP following vaccination (particularly reported with adenoviral vector vaccines like AstraZeneca) and temporary platelet count dips in pre-existing ITP patients. However, the absolute risk is small — estimated at approximately 1-3 per 100,000 vaccinations — and must be weighed against COVID-19's significant risk for immunocompromised or chronic health condition patients including those on Platify 50. Current UK guidance supports COVID-19 vaccination for ITP patients — it is generally recommended but with specific precautions: platelet count should ideally be above 30 × 10⁹/L before vaccination; platelet count should be checked 48-72 hours post-vaccination; mRNA vaccines (Pfizer, Moderna) are generally preferred over adenoviral vector vaccines for pre-existing ITP patients due to the lower documented ITP risk; and any new bruising, petechiae, or unexplained bleeding following vaccination should be reported promptly to the Leeds haematology team. The consensus from British Society for Haematology guidelines is that vaccination benefits outweigh the small ITP risk for most patients on Platify 50.
